My memory is that they said they had enough funds to get beyond...

My memory is that they said they had enough funds to get beyond the interim AD study and if that was successful that’s effectively when they would need more funds to execute the USA leg of the study. They were to remain only in Australia primarily due to also getting the cash tax rebate. Now they have doubled down with our money by changing that strategy for a much higher risk with supposedly no reduction in the overall time to endpoint in the AD trial! Higher risk and more expensive as not only is USA trials much higher but also there is no cash tax rebate. Why go to the USA now unless they overestimated their capability to enlist within Australia for the interim analysis requirements by mid 2025. Again a poor reflection on management IMO. Damage now done with further dilution to long time suffering retail shareholders as no doubt this raise will again be dilutionary to us retail shareholders!